PUBLISHER: BIS Research | PRODUCT CODE: 1279014
PUBLISHER: BIS Research | PRODUCT CODE: 1279014
Functional Genomics Market - A Global and Regional Analysis: Focus on Product, Technology, Application, End User and Country Analysis - Analysis and Forecast, 2023-2033
“The global functional genomics market is estimated to reach $46.24 billion in 2033, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 14.04% during the forecast period 2023-2033.”
Growth in the global functional genomics market is driven by the increasing investments by the government and private organizations and the increasing realization of the need for personalised medicine and therapies.
USP of the Report
- Vast segmentation of the report
- Product specifications and comparative analysis
- Market dynamic analysis of the opportunities, trends, and challenges in the market
- Competitive benchmarking of key players for each product type
- Growth share analysis for key segments
Analyst Perspective
According to Swati Sood, Principal Analyst, BIS Research, "Global functional genomics market is a one of the major markets going to be involved in the revolution of precision medicine in the coming years. Functioanl genomics helps us understand the granulality of the interactions between DNA, RNA and proteins which is the base of all the drug discovery, precision medicine and targeted therapy research among many pother applications of the field."
Key Companies Operating in The Market
The key players in the global functional genomics market have been analyzed and profiled in the study, consisting of most product-based companies. Moreover, a detailed competitive benchmarking of the players operating in the global functional genomics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
The key players profiled in the report include Agilent Technologies, Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher. (Integrated DNA Technologies, Inc.), Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Illumina, Inc., Merck KGaA, MRM Proteomics, Pacific Biosciences of California, Inc., Perkin Elmer, Inc., Promega Corporation, QIAGEN, and Thermo Fisher Scientific Inc.
Key Questions Answered in the Report:
- How is the functional genomics market revolutionizing precision medicine therapeutics, influencing disease diagnosis and treatment, and other applications landscapes?
- What are the major market drivers, challenges, and opportunities in the global functional genomics market?
- What are the underlying structures resulting in the emerging trends within the global functional genomics market?
- How did the COVID-19 pandemic impact the global functional genomics market?
- What are the key development strategies that are being implemented by major players to sustain themselves in the competitive market?
- What are the key regulatory implications in developed and developing regions pertaining to the use of functional genomics products?
- What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region in the market?
- What will be the growth rate of the global functional genomics market during the forecast period?
- How is each segment of the market expected to grow during the forecast period 2023-2033, and what revenue is anticipated to be generated by each of the segments?
- What are the growth opportunities for the functional genomics companies in the region of their operation?
- Who are the leading players with significant offerings in the global functional genomics market?
- Which companies are anticipated to be highly disruptive in the future, and why?
Global Functional Genomics Market Industry Overview
In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033. The growth in the global functional genomics market is expected to be driven by its increased applications especially in targeted therapy and precision medicine.
Market Lifecycle Stage
Functional genomics is the study of genes and their interactions in different biological processes. The field aims to narrow down the candidate genes or regions from the entire genome that can be analyzed in detail to understand the working of various biological processes. The workings of individual components of a biological system including various interactions at the DNA, RNA, and proteins level is analyzed at the genotypic as well as the phenotypic level. The field is focused on the dynamics of gene products which can be at a specific developmental stage during a disease. Functional genomics is used to link phenotypes to genotypes using the study findings.
According to BIS Research functional genomics products are used in DNA level (epigenomics), RNA level (transcriptomics), protein level (proteomics) or metabolite level (metabolomics). This includes all the products used in these fields' workflow before bioinformatics and data analysis. Together all these fields describe the transcripts, metabolites, and proteins of any biological system. The integration of all these pieces makes up the entire biological system that is being studied which makes up the field of functional genomics.
Impact
- For instance, in May 2022, Thermo Fisher Scientific, Inc. partnered with Qatar Foundation to develop a pan-Arab genotyping array. The intent behind this product launch was to be a cost-effective alternative to whole-genome sequencing and to provide greater diversity in genome-wide research studies under Qatar Genome Program.
- In September 2022, Illumina Inc. introduced the NovaSeqX Series (NovaSeq X and NovaSeq X Plus), which are next-generation sequencers designed for large-scale production. With the capability to sequence over 20,000 genomes per year, this new technology offers unparalleled accuracy and scalability.
Impact of COVID-19
In March 2019, the world was hit by a storm with the Sars-CoV-2 virus, which led to the entire world being shut down and everybody getting tested for the virus. As the amount of testing increased, it became important to increase the pace of testing as well. To do this, next-generation sequencers were set up at many clinical and diagnostic centers to sequence the genomes and transcriptomes of the virus as well as the infected patients to understand and procure treatments.
Recently, NGS technologies are increasingly being used for clinical diagnosis. The overall popularity of NGS sequencing for genome and transcriptome sequencing was increased during COVID-19 because of its use in the detection of coronavirus by the methods such as SARS-CoV-2 surveillance, detection, and the detection of new viruses.
In response to the COVID-19 pandemic and the impact on medical research at the National Institutes of Health (NIH) and the National Cancer Institute (NCI) both extended grant application deadlines, laid back reporting requirements, and offered flexibility on how the grant money is spent. The national government supported research work and offered medical researchers the flexibility to implement their skill set and knowledge in studying SARS-CoV-2. Due to this, the use of NGS during COVID-19 ended up increasing due to its use in COVID-19 testing.
In fact, even now, after the pandemic has subsided the effect lingers and the use of sequencing instruments is not expected to go down but to keep increasing over the next decade enhancing the fields for epigenomics, transcriptomics, proteomics and metabolomics as well.
Market Segmentation:
Segmentation 1: by Product
- Kits and Assays
- Instruments
As of 2022, the global functional genomics market (by product) was dominated by the kits and assays segment, holding a 58.12% market share.
Segmentation 2: by Technology
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Microarray
- Other
The global functional genomics market (by technology) is expected to be dominated by the next-generation sequencing (NGS) segment during the forecast period 2023-2033. This is because it is the most efficient and accurate technology currently available when it comes to gene analysis.
Segmentation 3: by Application
- Transcriptomics
- Epigenomics
- Proteomics
- Metabolomics
The global functional genomics market (by application) is expected to be dominated by the transcriptomics segment in the market during the forecast period 2023-2033. This is because this is one the oldest fields of functional genomics with much research and efficient tools already done, additionally it is easier to analyse RNAs as compared to proteins, thus the high revenue of this segment.
Segmentation 4: by End User
- Academic & Research Institutions
- Biotechnology and Biopharmaceutical Companies
- Other End Users
As of 2022, the global functional genomics market (by end user) was dominated by the academic and research institutions segment, holding a 60.32% market share.
Segmentation 5: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World
North America is expected to dominate the global functional genomics market with a revenue of $4.21 billion in 2022. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 15.27% during the forecast period 2023-2033.
Recent Developments in Global Functional Genomics Market
- In September 2022, Thermo Fisher Scientific partnerered with the joint effort of Acdemia Sinica and multiple hospitals across the country, i.e., Taiwan Precision Medicine Initiative (TPMI) to advance the next phase of the large-scale predictive genomics study. The intent behind this partnership was to support its goal of genotyping 1 million people in Taiwan. TPMI reached the milestone of enrolling more than 500,000 participants in July, making it the largest study of its kind outside of the United States and Europe.
- In March 2022, Thermo Fisher Scientific collaborated with Symphogen and Servier to provide biopharmaceutical discovery and development laboratories with advanced tools and simplified processes for effective analysis of intricate therapeutic proteins, thereby supporting their research efforts.
- In July 2021, Pacific Biosciences of California, Inc. has sighned a agreement to acquire Omniome. This acquitision is likley to expand the portfolio in epigenetics segments
- In October 2022, Oxford Nanopore Technologies introduced the new PromethION 2 ("P2") Solo sequencer in the market. It is a high-yield sequencer that provides real-time whole genome sequencing, enabling more than just basic DNA analysis. With the capacity for comprehensive analysis of genetic variants, transcriptomic and epigenetic data on a single platform, this technology is aimed at driving scientific discovery to improve lives.
- In September 2022, Illumina Inc. introduced the NovaSeqX Series (NovaSeq X and NovaSeq X Plus), which are next-generation sequencers designed for large-scale production. With the capability to sequence over 20,000 genomes per year, this new technology offers unparalleled accuracy and scalability.
Demand - Drivers and Limitations
Following are the demand drivers for the global functional genomics market:
- Integration of Multi-omics Approaches for Patient Stratification
- Increasing Popularity of Epigenetics Leading to Vast Usage
- Increased Technological Advancements and Government Initiatives in the Functional Genomics Ecosystem
The market is expected to face some limitations too due to the following challenges:
- Limitation in Implementation of Data in Proteomics and Metabolomics
- Regulatory Compliance issues related to Functional Genomics Technology
How can this report add value to an organization?
- Product/Innovation Strategy: The report considers functional genomics kits and assays-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of more efficient instruments and tools of functional genomics is increasing researchers' trust in functional genomics.
- Growth/Marketing Strategy: The key components in functional genomics are the kits and assays along with the instruments for sample analysis. The advancements in the overall fucntioncal genomics ecosystem are influencing the growth of this market.
- Competitive Strategy: The key players in the global functional genomics market have been analyzed and profiled in the study, consisting of most product-based companies. Moreover, a detailed competitive benchmarking of the players operating in the global functional genomics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.
Key Companies Profiled:
|
|
Table of Contents
1 Markets
- 1.1 Product Definition
- 1.2 Inclusion and Exclusion Criteria
- 1.3 Market Scope
- 1.3.1 Scope of the Study
- 1.3.2 Key Questions Answered in the Report
- 1.4 Research Methodology
- 1.4.1 Global Functional Genomics Market: Research Methodology
- 1.4.2 Data Sources
- 1.4.3 Market Estimation Model
- 1.4.4 Criteria for Company Profiling
2 Market Overview
- 2.1 Functional Genomics Workflow Analysis
- 2.2 Future Potential
- 2.3 Impact of Functional Genomics
- 2.3.1 Gene Therapy
- 2.3.2 Drug Discovery and Development
- 2.3.3 Gene Expression
- 2.3.4 Single-Cell Analysis
3 Industry Insight
- 3.1 Legal and Regulatory Framework of Genetic Tests
- 3.1.1 Diagnostic Test
- 3.2 Reimbursement Scenario
4 Market Dynamics
- 4.1 Overview
- 4.2 Market Drivers
- 4.2.1 Integration of Multi-omics Approaches for Patient Stratification
- 4.2.2 Increasing Popularity of Epigenetics Leading to Vast Usage
- 4.2.3 Increased Technological Advancements and Government Initiatives in the Functional Genomics Ecosystem
- 4.3 Market Challenges
- 4.3.1 Limitations in Implementation of Data in Proteomics and Metabolomics
- 4.3.2 Regulatory Compliance Issues Related to Functional Genomics Technology
- 4.4 Market Opportunities
- 4.4.1 Upsurge in Proteomic Approaches in Biomarker Discovery
- 4.4.2 Rising Opportunities for Translational and Clinical Studies
5 Competitive Insight
- 5.1 Overview
- 5.2 Key Strategies and Developments
- 5.2.1 Synergistic Activities
- 5.2.2 Product Launches and Product Approvals
- 5.2.3 Expansions
- 5.2.4 Mergers and Acquisitions
- 5.2.5 Investments and Other Activities
- 5.3 Market Share Analysis (2022)
6 Global Functional Genomics Market (By Product), 2022-2033
- 6.1 Overview
- 6.1.1 Kits and Assays
- 6.1.2 Instruments
7 Global Functional Genomics Market (By Technology), 2022-2033
- 7.1 Overview
- 7.1.1 Next-Generation Sequencing (NGS)
- 7.1.2 Polymerase Chain Reaction (PCR)
- 7.1.3 Microarray
- 7.1.4 Other Technologies
8 Global Functional Genomics Market (by Application), 2022-2033
- 8.1 Overview
- 8.2 Epigenomics
- 8.3 Transcriptomics
- 8.4 Proteomics
- 8.5 Metabolomics
9 Global Functional Genomics Market (by End User), 2022-2033
- 9.1 Overview
- 9.2 Academic and Research Institutions
- 9.3 Biotechnology and Biopharmaceutical Companies
- 9.4 Other End Users (Hospitals, Clinics, and Diagnostic Labs)
10 Global Functional Genomics Market (By Region), 2022-2033
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 U.K.
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest-of-Europe
- 10.4 Asia-Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Singapore
- 10.4.6 Rest-of-Asia-Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest-of-Latin America
- 10.6 Rest-of-the-World
11 Company Profiles
- 11.1 Overview
- 11.2 Agilent Technologies, Inc.
- 11.2.1 Company Overview
- 11.2.2 Role of Agilent Technologies, Inc. in the Global Functional Genomics Market
- 11.2.3 Financials
- 11.2.4 Key Insights about the Financial Health of the Company
- 11.2.5 Recent Developments
- 11.2.6 Analyst Perspective
- 11.3 Becton, Dickinson and Company (BD)
- 11.3.1 Company Overview
- 11.3.2 Role of Becton, Dickinson and Company (BD) in the Global Functional Genomics Market
- 11.3.3 Financials
- 11.3.4 Key Insights about the Financial Health of the Company
- 11.3.5 Analyst Perspective
- 11.4 Bio-Rad Laboratories, Inc.
- 11.4.1 Company Overview
- 11.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Functional Genomics Market
- 11.4.3 Financials
- 11.4.4 Key Insights about the Financial Health of the Company
- 11.4.5 Recent Developments
- 11.4.6 Analyst Perspective
- 11.5 Danaher. (Integrated DNA Technologies, Inc.)
- 11.5.1 Company Overview
- 11.5.2 Role of Danaher. (Integrated DNA Technologies, Inc.) in the Global Functional Genomics Market
- 11.5.3 Financials
- 11.5.4 Key Insights about the Financial Health of the Company
- 11.5.5 Analyst Perspective
- 11.6 Exact Sciences Corporation
- 11.6.1 Company Overview
- 11.6.2 Role of Exact Sciences Corporation in the Global Functional Genomics Market
- 11.6.3 Financials
- 11.6.4 Key Insights about the Financial Health of the Company
- 11.6.5 Recent Developments
- 11.6.6 Analyst Perspective
- 11.7 F. Hoffmann-La Roche Ltd
- 11.7.1 Company Overview
- 11.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Functional Genomics Market
- 11.7.3 Financials
- 11.7.4 Key Insights about the Financial Health of the Company
- 11.7.5 Recent Developments
- 11.7.6 Analyst Perspective
- 11.8 Illumina, Inc.
- 11.8.1 Company Overview
- 11.8.2 Role of Illumina, Inc. in the Global Functional Genomics Market
- 11.8.3 Financials
- 11.8.4 Key Insights about the Financial Health of the Company
- 11.8.5 Recent Developments
- 11.8.6 Analyst Perspective
- 11.9 Merck KGaA
- 11.9.1 Company Overview
- 11.9.2 Role of Merck KGaA in the Global Functional Genomics Market
- 11.9.3 Financials
- 11.9.4 Key Insights about the Financial Health of the Company
- 11.9.5 Analyst Perspective
- 11.1 MRM Proteomics
- 11.10.1 Company Overview
- 11.10.2 Role of MRM Proteomics in the Global Functional Genomics Market
- 11.10.3 Analyst Perspective
- 11.11 Pacific Biosciences of California, Inc.
- 11.11.1 Company Overview
- 11.11.2 Role of Pacific Biosciences of California, Inc. in the Global Functional Genomics Market
- 11.11.3 Financials
- 11.11.4 Key Insights about the Financial Health of the Company
- 11.11.5 Recent Developments
- 11.11.6 Analyst Perspective
- 11.12 Perkin Elmer, Inc.
- 11.12.1 Company Overview
- 11.12.2 Role of PerkinElmer, Inc. in the Global Functional Genomics Market
- 11.12.3 Financials
- 11.12.4 Key Insights about the Financial Health of the Company
- 11.12.5 Analyst Perspective
- 11.13 Promega Corporation
- 11.13.1 Company Overview
- 11.13.2 Role of Promega Corporation in the Global Functional Genomics Market
- 11.13.3 Analyst Perspective
- 11.14 QIAGEN
- 11.14.1 Company Overview
- 11.14.2 Role of QIAGEN in the Global Functional Genomics Market
- 11.14.3 Financials
- 11.14.4 Key Insights about the Financial Health of the Company
- 11.14.5 Recent Developments
- 11.14.6 Analyst Perspective
- 11.15 Thermo Fisher Scientific Inc.
- 11.15.1 Company Overview
- 11.15.2 Role of Thermo Fisher Scientific Inc. in the Global Functional Genomics Market
- 11.15.3 Financials
- 11.15.4 Key Insights about the Financial Health of the Company
- 11.15.5 Recent Developments
- 11.15.6 Analyst Perspective
List of Figures
- Figure 1: Global Functional Genomics Market, $Billion, 2023 and 2033
- Figure 2: Biological Features of Functional Genomics Approaches
- Figure 3: Share of Global Functional Genomics Market (By Product), $Billion, 2022 and 2033
- Figure 4: Share of Global Functional Genomics Market (by Application), $Billion, 2022 and 2033
- Figure 5: Share of Global Functional Genomics Market (by Region), 2022
- Figure 6: Global Functional Genomics Market Segmentation
- Figure 7: Global Functional Genomics Market: Research Methodology
- Figure 8: Primary Research Methodology
- Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 10: Top-Down Approach (Segment-Wise Analysis)
- Figure 11: Epigenomics Workflow
- Figure 12: Transcriptomics Workflow
- Figure 13: Proteomics Workflow
- Figure 14: Metabolomics Workflow
- Figure 15: U.S. Federal Agencies and their Role in Genetic Tests
- Figure 16: U.S. FDA Regulatory Workflow for Diagnostic Tests
- Figure 17: Global Functional Genomics Market Dynamics
- Figure 18: Rate of Adoption of Multi-omics Approach for Patient Stratification and Research
- Figure 19: Total Number of Publications Published Each Year for Cancer Research Through Multi-omics
- Figure 20: Total Epigenetics Publications to Understand the Development of Age-Related Chronic Diseases
- Figure 21: Total Number of Clinical Trials under Drug Development for Genomics, 2016-2022
- Figure 22: Share of Key Developments and Strategies, January 2020-March 2023
- Figure 23: Share of Synergistic Activities (by Company), January 2020-March 2023
- Figure 24: Share of Product Launches and Product Approvals (by Company), January 2020-March 2023
- Figure 25: Share of Expansions (by Company), January 2020-March 2023
- Figure 26: Share of Mergers and Acquisitions (by Company), January 2020-March 2023
- Figure 27: Share of Investments and Other Activities (by Company), January 2020-March 2023
- Figure 28: Market Share Analysis for Global Functional Genomics Market, $Billion, 2022
- Figure 29: Global Functional Genomics Market (by Product)
- Figure 30: Share of Global Functional Genomics Market (by Product), $Billion, 2022 and 2033
- Figure 31: Global Functional Genomics Market (Kits and Assays), ($Billion), 2022-2033
- Figure 32: Global Functional Genomics Market (Instruments), ($Billion), 2022-2033
- Figure 33: Global Functional Genomics Market (by Technology)
- Figure 34: Share of Global Functional Genomics Market (by Technology), $Billion, 2022 and 2033
- Figure 35: Global Functional Genomics Market (Next-Generation Sequencing (NGS)), $Billion, 2022-2033
- Figure 36: Global Functional Genomics Market (Polymerase Chain Reaction (PCR)), $Billion, 2022-2033
- Figure 37: Global Functional Genomics Market (Microarray), $Billion, 2022-2033
- Figure 38: Global Functional Genomics Market (Other Technologies), $Billion, 2022-2033
- Figure 39: Global Functional Genomics Market (by Application)
- Figure 40: Global Functional Genomics Market (by Application), $Billion, 2022 and 2033
- Figure 41: Global Functional Genomics Market (Epigenomics), $Billion, 2022-2033
- Figure 42: Global Functional Genomics Market (Transcriptomics), $Billion, 2022-2033
- Figure 43: Global Functional Genomics Market (Proteomics), $Billion, 2022-2033
- Figure 44: Global Functional Genomics Market (Metabolomics), $Billion, 2022-2033
- Figure 45: Global Functional Genomics Market (by End User)
- Figure 46: Global Functional Genomics Market (by End User), $Billion, 2022 and 2033
- Figure 47: Global Functional Genomics Market (Academic and Research Institutions), $Billion, 2022-2033
- Figure 48: Global Functional Genomics Market (Biotechnology and Biopharmaceutical Companies), $Billion, 2022-2033
- Figure 49: Global Functional Genomics Market (Other End Users), $Billion, 2022-2033
- Figure 50: Global Functional Genomics Market Snapshot (by Region)
- Figure 51: Global Functional Genomics Market (by Region), $Billion, 2023-2033
- Figure 52: North America Functional Genomics Market, $Billion, 2023-2033
- Figure 53: North America Functional Genomics Market (by Country), $Billion, 2023-2033
- Figure 54: U.S. Functional Genomics Market, $Billion, 2022-2033
- Figure 55: Canada Functional Genomics Market, $Billion, 2022-2033
- Figure 56: Europe Functional Genomics Market, $Billion, 2022-2033
- Figure 57: Europe Functional Genomics Market (by Country), $Billion, 2022-2033
- Figure 58: Germany Functional Genomics Market, $Billion, 2022-2033
- Figure 59: France Functional Genomics Market, $Billion, 2022-2033
- Figure 60: U.K. Functional Genomics Market, $Billion, 2022-2033
- Figure 61: Italy Functional Genomics Market, $Billion, 2022-2033
- Figure 62: Spain Functional Genomics Market, $Billion, 2022-2033
- Figure 63: Rest-of-Europe Functional Genomics Market, $Billion, 2022-2033
- Figure 64: Asia-Pacific Functional Genomics Market, $Billion, 2022-2033
- Figure 65: Asia-Pacific Functional Genomics Market (by Country), $Billion, 2022-2033
- Figure 66: China Functional Genomics Market, $Billion, 2022-2033
- Figure 67: Japan Functional Genomics Market, $Billion, 2022-2033
- Figure 68: India Functional Genomics Market, $Billion, 2022-2033
- Figure 69: Australia Functional Genomics Market, $Billion, 2022-2033
- Figure 70: Singapore Functional Genomics Market, $Billion, 2022-2033
- Figure 71: Rest-of-Asia-Pacific Functional Genomics Market, $Billion, 2022-2033
- Figure 72: Latin America Functional Genomics Market, $Billion, 2022-2033
- Figure 73: Latin America Functional Genomics Market Share (by Country), $Million, 2022-2033
- Figure 74: Brazil Functional Genomics Market, $Million, 2022-2033
- Figure 75: Mexico Functional Genomics Market, $Million, 2022-2033
- Figure 76: Rest-of-Latin America Functional Genomics Market, $Million, 2022-2033
- Figure 77: Rest-of-the-World Functional Genomics Market, $Billion, 2022-2033
- Figure 78: Global Functional Genomics Market, Total Number of Key Companies Profiled
- Figure 79: Agilent Technologies, Inc.: Product Portfolio
- Figure 80: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
- Figure 81: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 82: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 83: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 84: Becton, Dickinson and Company (BD): Product Portfolio
- Figure 85: Becton, Dickinson and Company (BD).: Overall Financials, $Million, 2020-2022
- Figure 86: Becton, Dickinson and Company (BD).: Revenue (by Segment), $Million, 2020-2022
- Figure 87: Becton, Dickinson and Company (BD).: Revenue (by Region), $Million, 2020-2022
- Figure 88: Becton, Dickinson and Company (BD).: R&D Expenditure, $Million, 2020-2022
- Figure 89: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 90: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
- Figure 91: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 92: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 93: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 94: Danaher. (Integrated DNA Technologies, Inc.): Product Portfolio
- Figure 95: Danaher. (Integrated DNA Technologies, Inc.): Overall Financials, $Million, 2020-2022
- Figure 96: Danaher. (Integrated DNA Technologies, Inc.): Revenue (by Segment), $Million, 2020-2022
- Figure 97: Danaher. (Integrated DNA Technologies, Inc.): Revenue (by Region), $Million, 2020-2022
- Figure 98: Danaher. (Integrated DNA Technologies, Inc.): R&D Expenditure, $Million, 2020-2022
- Figure 99: Exact Sciences Corporation: Product Portfolio
- Figure 100: Exact Sciences Corporation: Overall Financials, $Million, 2020-2022
- Figure 101: Exact Sciences Corporation: Revenue (by Segment), $Million, 2020-2022
- Figure 102: Exact Sciences Corporation: Revenue (by Region), $Million, 2020-2022
- Figure 103: Exact Sciences Corporation: R&D Expenditure, $Million, 2020-2022
- Figure 104: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 105: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
- Figure 106: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
- Figure 107: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
- Figure 108: Illumina, Inc.: Product Portfolio
- Figure 109: Illumina, Inc.: Overall Financials, $Million, 2020-2022
- Figure 110: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 111: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 112: Illumina, Inc. (GRAIL, LLC.): R&D Expenditure, $Million, 2020-2022
- Figure 113: Merck KGaA: Product Portfolio
- Figure 114: Merck KGaA: Overall Financials, $Million, 2020-2022
- Figure 115: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
- Figure 116: Merck KGaA: Revenue (by Region), $Million, 2020-2022
- Figure 117: Merck KGaA: R&D Expenditure, $Million, 2020-2022
- Figure 118: MRM Proteomics: Product Portfolio
- Figure 119: Pacific Biosciences of California, Inc: Product Portfolio
- Figure 120: Pacific Biosciences of California, Inc.: Overall Financials, 2020-2022
- Figure 121: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2020-2022
- Figure 122: Pacific Biosciences of California, Inc.: Revenue (by Region), 2020-2022
- Figure 123: Pacific Biosciences of California, Inc.: R&D Expenditure, 2020-2022
- Figure 124: Perkin Elmer, Inc.: Product Portfolio
- Figure 125: PerkinElmer, Inc.: Overall Financials, $Million, 2020-2022
- Figure 126: PerkinElmer, Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 127: PerkinElmer, Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 128: PerkinElmer, Inc.: R&D Expenditure, $Million, 2020-2022
- Figure 129: Promega Corporation: Product Portfolio
- Figure 130: QIAGEN.: Product Portfolio
- Figure 131: QIAGEN: Overall Financials, $Million, 2019-2021
- Figure 132: QIAGEN: Revenue (by Segment), $Million, 2019-2021
- Figure 133: QIAGEN: Revenue (by Region), $Million, 2019-2021
- Figure 134: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 135: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 136: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
- Figure 137: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
- Figure 138: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
- Figure 139: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
List of Tables
- Table 1: Global Functional Genomics Market: Impact Analysis
- Table 2: Technological Trends in Global Functional Genomics Market
- Table 3: Technological Advancements in the Functional Genomics Ecosystem
- Table 4: Initiatives Taken by the Government in Functional Genomics
- Table 5: Cancers and Their Most Common Biomarker Tests
- Table 6: Kits and Assays Offered by Key Players
- Table 7: Instruments Offered by Key Players
- Table 8: Next-Generation Sequencing (NGS) Based Products for Functional Genomics
- Table 9: Polymerase Chain Reaction (PCR) Based Products for Functional Genomics
- Table 10: Microarray-Based Products for Functional Genomics
- Table 11: North America: Market Dynamics
- Table 12: Europe: Market Dynamics
- Table 13: Asia-Pacific: Market Dynamics
- Table 14: Latin America: Market Dynamics
